Nathan R Foster - JoVE Visualize

Showing results (51-60 of 89) with videos related to

Pageof 9

Sort By:

Gynecologic Oncology|May 3, 2017

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007

Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar, Donald W Northfelt, Steven E Schild, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942Michael G Haddock, Revathi Swaminathan, Nathan R Foster, et al.

Ebiomedicine|November 11, 2019

Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma developmentTianshun Zhang, Qiushi Wang, Wei-Ya Ma, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2008

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)Aminah Jatoi, Shaker R Dakhil, Nathan R Foster, et al.

Cancer Biology & Therapy|October 11, 2021

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteersDavid S Weinberg, Nathan R Foster, Gary Della'Zanna, et al.

The Oncologist|November 25, 2016

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)Preet Paul Singh, Qian Shi, Nathan R Foster, et al.

The Annals of Thoracic Surgery|April 23, 2016

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.

Cancer|May 12, 2017

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.

Cancer|January 29, 2008

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno, Robert Delaune, Jeff A Sloan, et al.

Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:

Pageof 9

Gynecologic Oncology|May 3, 2017

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007

Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar, Donald W Northfelt, Steven E Schild, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942Michael G Haddock, Revathi Swaminathan, Nathan R Foster, et al.

Ebiomedicine|November 11, 2019

Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma developmentTianshun Zhang, Qiushi Wang, Wei-Ya Ma, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2008

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)Aminah Jatoi, Shaker R Dakhil, Nathan R Foster, et al.

Cancer Biology & Therapy|October 11, 2021

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteersDavid S Weinberg, Nathan R Foster, Gary Della'Zanna, et al.

The Oncologist|November 25, 2016

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)Preet Paul Singh, Qian Shi, Nathan R Foster, et al.

The Annals of Thoracic Surgery|April 23, 2016

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.

Cancer|May 12, 2017

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.

Cancer|January 29, 2008

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno, Robert Delaune, Jeff A Sloan, et al.

Pageof 9